Overview

Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial

Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
The ATTEMPT (Adolescent Type 1 diabetes Treatment with SGLT2i for hyperglycEMia & hyPerfilTration Trial) is a multi-center, double-blinded, randomized, placebo-controlled trial to evaluate the effect of treatment with Dapagliflozin when compared to placebo, in combination with adjustable insulin, on measured GFR in adolescents with T1D 12 to <19 years of age over a 16-week treatment period.
Phase:
Phase 3
Details
Lead Sponsor:
The Hospital for Sick Children
Collaborators:
Canadian Institutes of Health Research (CIHR)
Juvenile Diabetes Research Foundation
Treatments:
2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
Dapagliflozin